These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 19525681

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
    Van Thiel D, Kalodiki E, Wahi R, Litinas E, Haque W, Rao G.
    Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
    Perzborn E, Kubitza D, Misselwitz F.
    Hamostaseologie; 2007 Sep; 27(4):282-9. PubMed ID: 17938768
    [Abstract] [Full Text] [Related]

  • 9. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Abrams PJ, Emerson CR.
    Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
    Kakar P, Watson T, Lip GY.
    Curr Opin Investig Drugs; 2007 Mar; 8(3):256-65. PubMed ID: 17408122
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
    Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK.
    Thromb Haemost; 2011 Mar; 105(3):444-53. PubMed ID: 21136019
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Rivaroxaban: mode of action].
    Drouet L.
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [Abstract] [Full Text] [Related]

  • 20. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT, Dobromirski M.
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.